359
Views
5
CrossRef citations to date
0
Altmetric
Cardiovascular Medicine

Incidence rate of hospitalization and mortality in the first year following initial diagnosis of cardiac amyloidosis in the US claims databases

, , , , , & show all
Pages 1275-1281 | Received 02 Dec 2020, Accepted 01 Apr 2021, Published online: 23 Apr 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (4)

Sandeep Appunni, Muni Rubens, Venkataraghavan Ramamoorthy, Anshul Saxena, Mayur Doke, Mukesh Roy, Juan Gabriel Ruiz-Pelaez, Yanjia Zhang, Ashfaq Ahmed, Zhenwei Zhang, Peter McGranaghan, Sandra Chaparro & Javier Jimenez. (2023) Adverse Outcomes in Hospitalizations for Amyloid-Related Heart Failure. The American Journal of Cardiology 203, pages 169-174.
Crossref
Tse-Hao Lee, Yuh-Feng Wang, Lien-Hsin Hu, Nan-Jing Peng, Chih-Yung Chang & Wen-Sheng Huang. (2023) Follow-up Tc-99 m pyrophosphate cardiac scan for patients with transthyretin cardiac amyloidosis treated with tafamidis. Japanese Journal of Radiology.
Crossref
Therese Bittermann, James D. Lewis, Cynthia Levy & David S. Goldberg. (2023) Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis. Hepatology 77:2, pages 367-378.
Crossref
Morie A. Gertz. (2022) Role of Daratumumab in Cardiac AL Amyloidosis. JACC: CardioOncology 4:4, pages 488-490.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.